Switzerland's Roche agrees to acquire US-based PathAI

Roche Holding AG

07/05/2026 06:48

ZURICH, May 7 (Reuters) - Swiss pharmaceutical giant Roche ROPC.S said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further milestone payments of up to $300 million.

The acquisition builds on a five-year partnership between Roche and PathAI that was scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms.

The deal is expected to close in the second half of 2026, and PathAI - based on Boston, Massachusetts - is due to become part of Roche's diagnostics division.

Roche said the acquisition strengthens its position in digital pathology, which is helping to transform manual workflows into fully automated, AI-driven processes.

"Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens," Matt Sause, CEO of Roche Diagnostics, said in a statement.

 (Writing by Dave Graham, Editing by Friederike Heine)

 ((dave.graham@thomsonreuters.com; Reuters Messaging: dave.graham.thomsonreuters.com@reuters.net))